Brought to you by 
Vernalis sells, then buys back European frovatriptan royalties
27 Apr 2021
Executive Summary
Moving ahead with a major restructuring project to build up money for its early-stage neurology pipeline, Vernalis PLC has agreed to sell investor Paul Capital Healthcare future royalty payments on its migraine drug frovatriptan in exchange for €18.4mm ($29.1mm) cash.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Withdrawn
Deal Type
-
Financing
- Royalty Sale
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Vernalis sells, then buys back European frovatriptan royalties
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice